scholarly journals Evaluation of In-vitro Anti-cancer activity of Ethanolic Extract of Corallocarpus epigaeus on Chronic Myeloid Leukaemia K562 Cell lines

2015 ◽  
Vol 02 (01) ◽  
pp. 08-13
Author(s):  
Chandra S Kothapalli Banoth ◽  
Devanna Nayakanti ◽  
Venkata.Naga Anantha ◽  
Sandhya R Nandyalac ◽  
Sreenivasa K Oruganti ◽  
...  
2017 ◽  
Vol 6 (2) ◽  
pp. 78-83
Author(s):  
N Ramya ◽  
◽  
Priyadharshini ◽  
R Prakash ◽  
R Dhivya ◽  
...  

Breast cancer is second most common in women and accounts for 23% of all occurring cancers in women. Patients with breast cancer have increasingly shown resistance and high toxicity to chemotherapeutic drugs. Plant-derived products have proved to be an important source of anti-cancer drugs. The present study was to investigate the anti cancer activity of ethanolic extract of Trachyspermum ammi against MCF-7 cell lines. The preliminary phytochemical studies of ethanolic extract of Trachyspermum ammi showed the presence of flavanoids, alkaloids, glycosides, steroids, carbohydrates, phenols, tannins and terpenes. The IC50 concentration of ethanolic extract of Trachyspermum ammi was determined by MTT assay. The results showed the greater degree of cytotoxicity at the dose of 25µg/ml of Trachyspermum ammi and it has been taken as IC50 value for our further study. Then, we also evaluated the apoptotic effect by measuring the morphological changes, cell viability rates using light and fluorescent microscopical studies and DNA fragmentation by using gel electrophoresis method. The ethanolic extract of Trachyspermum ammi showed significant signs of apoptosis such as cell shrinkage, membrane blebbing and nuclei DNA fragmentation. Further, we analyze the gene expression mRNA levels by using RT-PCR method, it showed the expression of p53 was significantly (P<0.001) increased when compared with normal MCF-7 cell line. The expression of anti apoptotic gene Bcl-2 was significantly (P<0.01) reduced when compared with MCF-7 cell line. From this study we conclude that ethanolic extract of Trachyspermum ammi having significant anticancer activity against MCF-7 cell lines and it might be good therapeutic value for further investigation to develop natural compounds as a anti tumor agents.


2018 ◽  
Vol 6 (9) ◽  
pp. 79-87
Author(s):  
Y. Anil Kumar ◽  
Konda Ravi Kumar ◽  
Y. Sirisha ◽  
B. Gopikrishna ◽  
S. Yashita raga

2019 ◽  
Vol 224 ◽  
pp. 328-333 ◽  
Author(s):  
Sathyaraj Weslen Vedakumari ◽  
Rethinam Senthil ◽  
Sathiya Sekar ◽  
Chidambaram Saravana Babu ◽  
Thotapalli Parvathaleswara Sastry

Molecules ◽  
2021 ◽  
Vol 26 (3) ◽  
pp. 577
Author(s):  
Hamdoon A. Mohammed ◽  
Riaz A. Khan ◽  
Atef A. Abdel-Hafez ◽  
Marwa Abdel-Aziz ◽  
Eman Ahmed ◽  
...  

Zygophyllum coccineum, an edible halophytic plant, is part of the traditional medicine chest in the Mediterranean region for symptomatic relief of diabetes, hypertension, wound healing, burns, infections, and rheumatoid arthritis pain. The current study aimed to characterize Z. coccineum phytoconstituents, and the evaluations of the anti-microbial-biofilm, and anti-cancers bioactivities of the plant’s mother liquor, i.e., aqueous-ethanolic extract, and its subsequent fractions. The in silico receptors interaction feasibility of Z. coccineum major constituents with Staph GyraseB, and human topoisomerase-IIβ (h-TOP-IIβ) were conducted to confirm the plant’s anti-microbial and anti-cancer biological activities. Thirty-eight secondary metabolites of flavonoids, stilbene, phenolic acids, alkaloids, and coumarin classes identified by LC-ESI-TOF-MS spectrometric analysis, and tiliroside (kaempferol-3-O-(6′′′′-p-coumaroyl)-glucoside, 19.8%), zygophyloside-F (12.78%), zygophyloside-G (9.67%), and isorhamnetin-3-O-glucoside (4.75%) were identified as the major constituents. A superior biofilm obliteration activity established the minimum biofilm eradication concentration (MBEC) for the chloroform fraction at 3.9–15.63 µg/mL, as compared to the positive controls (15.63–31.25 µg/mL) against all the microbial strains that produced the biofilm under study, except the Aspergillus fumigatus. The aqueous-ethanolic extract showed cytotoxic effects with IC50 values at 3.47, 3.19, and 2.27 µg/mL against MCF-7, HCT-116, and HepG2 cell-lines, respectively, together with the inhibition of h-TOP-IIβ with IC50 value at 45.05 ng/mL in comparison to its standard referral inhibitor (staurosporine, IC50, 135.33 ng/mL). This conclusively established the anti-cancer activity of the aqueous-ethanolic extract that also validated by in silico receptor-binding predicted energy levels and receptor-site docking feasibility of the major constituents of the plant’s extract. The study helped to authenticate some of the traditional phytomedicinal properties of the anti-infectious nature of the plant.


2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 104-104 ◽  
Author(s):  
Paul Toren ◽  
Steven Pham ◽  
Soojin Kim ◽  
Hans Adomat ◽  
Amina Zoubeidi ◽  
...  

104 Background: Castrate resistant prostate cancer (CRPC) continues to be sensitive to anti-androgen therapy as evidenced by the recent successes of abiraterone acetate (AA) and enzalutamide (ENZ). VT-464 is a novel, non-steroidal, small molecule CYP17A1 inhibitor with selectivity for the lyase activity of this dual enzyme. The objective of this study was to evaluate the anti-cancer activity of VT-464 compared to AA in CRPC in vitro models that are ENZ-responsive and ENZ-resistant and in an ENZ-resistant xenograft model. Methods: In vitro studies used the human CRPC, C4-2, and ENZ-resistant cell lines, MR49C and MR49F cells, in androgen-free media. AR transcriptional activity was assessed by probasin luciferase. AR-related and steroidogenesis pathways were assessed by western blot and/or qRT-PCR. A MR49F xenograft model in castrate mice compared oral VT-464 treatment to vehicle and AA. Steroid concentrations were measured using LC-MS chromatography. Results: VT-464 demonstrated a greater decrease in AR transactivation compared to AA in C4-2 and both ENZ-resistant cell lines. A greater decrease in AR-dependent gene transcription occurred with VT-464 treatment compared to AA in all cell lines. Prostate-specific antigen (PSA) protein levels in vitro were also lower with VT-464. Gene transcripts StAR, CYP17A1, HSD17B3 and SRD5A1 increased following treatment with VT-464 both in vitro and in vivo. A greater increase was seen with VT-464 treatment compared to AA. In vivo results demonstrated greater tumor growth inhibition and decreased serum PSA levels in mice treated with oral VT-464 compared to AA. Steroid analysis revealed lower testosterone (T) and dihydrotestosterone (DHT) concentrations in C4-2 cells with VT-464 treatment compared to AA. In vivo, the intra-tumoral DHT and T levels were significantly lower in response to VT-464 or AA compared to vehicle, with the greatest decrease seen with VT-464. Conclusions: The selective CYP17 inhibitor VT-464 demonstrated anti-cancer activity in pre-clinical models of CRPC, lowering intratumoral T and DHT concentrations significantly in castrate mice. These results suggest greater androgen suppression and inhibition of AR axis signaling by VT-464 than by AA.


Sign in / Sign up

Export Citation Format

Share Document